Receive our newsletter – data, insights and analysis delivered to you

Covid-19 spread was aided by resistance to evidence of asymptomatic transmission

By Paul Dennis

30 June

Health officials and government authorities ignored the risk of asymptomatic transmission of Covid-19 despite mounting evidence from scientists across the world.

Acknowledgement of the risk would have necessitated drastic containment measures, something which government officials were reluctant to implement.

Timely response was the most crucial element for stopping the global spread of the disease.

Paul Romer, an economist, shared a New York Times article on how a two-month delay over public health response to Covid-19 led to its global spread.

The delay was due to faulty scientific assumptions and resistance towards new evidence on the evolving nature of the disease, which resulted in a sluggish response to controlling the spread of the virus.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Despite some scientists raising red flags over asymptomatic transmission, the warnings were dismissed by health officials and political leaders.

Asymptomatic transmission would have required more aggressive methods of containment including wearing of masks by healthy persons and restriction of international travel.

The reluctance of adopt such drastic measures was one of the main reasons for the global spread of the disease that has cost thousands of lives, the article adds.

 

Read more

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU